One recent study found overtreatment of type 2 diabetes among elderly patients, while another looked at how many patients with diabetes would be referred to a liver specialist under proposed European guidelines.
Two recent studies analyzed the renal effects of medications for type 2 diabetes, one finding lower rates of acute kidney injury with sodium-glucose co-transporter-2 inhibitors and the other finding reduced onset of macroalbuminuria with liraglutide.
Two studies compared heart failure rates in patients with and without type 2 diabetes, while a third looked at the risk of heart failure associated with various classes of glucose-lowering drugs.
ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.
In the past month, a new meta-analysis compared metformin to other diabetes drugs, and the FDA expanded metformin's indications in patients with reduced kidney function.
Managing diabetes can negatively impact quality of life for people with the disease, so doctors should consider a patient's treatment burden and the “whole person” when setting goals, 2 studies suggest.
The risks and consequences of hypoglycemia were described by several studies published recently.
Renal side effects of diabetes drugs were in the news in the past month, with one industry-funded study finding an association between empagliflozin and slower progression of kidney disease and the FDA strengthening an existing warning on risk of
Three recent studies reanalyzed past data about the effects of intensive glycemic control and published new findings about how and which patients may benefit.
Predicting cardiovascular events in patients with type 2 diabetes was the focus of multiple recent studies.